Tenecteplase for Stroke

(ESTER-DOAC Trial)

This trial tests the effectiveness and safety of tenecteplase for individuals who have experienced an acute ischemic stroke. Participants will receive either tenecteplase or a placebo to determine if the drug aids recovery within 4.5 hours of stroke onset. The trial focuses on those who have taken certain blood thinners (DOACs) like dabigatran or apixaban within the past 48 hours. Ideal candidates are those who have had a disabling stroke, can begin treatment quickly, and have recently used one of these blood thinners. As a Phase 3 trial, this study represents the final step before FDA approval, allowing participants to contribute to a potentially groundbreaking treatment.

The trial does not specify if you need to stop taking your current medications. However, it does require that participants have taken a Direct Oral AntiCoagulant (DOAC) within 48 hours before enrollment.

Previous studies have shown that tenecteplase (TNK) is safe for treating sudden strokes caused by blocked blood flow. Research indicates that TNK leads to excellent recovery outcomes at 90 days without raising safety concerns. Specifically, one study found that patients treated with TNK did not have a higher risk of bleeding-related side effects compared to those treated with another stroke medication, alteplase. Another study highlighted that TNK is safe and has a lower chance of causing bleeding in the brain than other treatments.

Tenecteplase is unique because it offers a faster and potentially more effective treatment for strokes compared to the current standard, which often includes alteplase. Unlike alteplase, Tenecteplase can be administered as a single, quick intravenous injection, making it easier and quicker to deliver in emergency situations. Researchers are excited about its promise to improve outcomes by potentially restoring blood flow more efficiently in patients suffering from acute ischemic stroke.

Research has shown that tenecteplase (TNK) effectively treats sudden strokes caused by blocked blood flow to the brain. In this trial, participants will receive either intravenous TNK or a placebo. Studies have found that TNK helps patients recover better within 90 days compared to treatments like alteplase. Specifically, TNK has been linked to higher success in opening blocked blood vessels in the brain, leading to better recovery and fewer long-term disabilities after a stroke. Additionally, TNK does not increase the risk of bleeding-related side effects, making it a promising option for stroke treatment.¹²³⁴⁶